

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.55)

09/914397

INTERNATIONAL APPLICATION NO.  
PCT/DE00/00116INTERNATIONAL FILING DATE  
07 January 2000 (07.01.00)PRIORITY DATE CLAIMED  
08 January 1999 (08.01.99)

## TITLE OF INVENTION

MOLECULAR-BIOLOGICAL MARKER FOR ANALYTICAL ELECTRON MICROSCOPY



APPLICANT(S) FOR DO/EO/US - Sabine BUB, Helmut TROESTER, Karsten RICHTER, Ansgar HAKING, Stefan RADDATZ, Manfred WIESSLER, Eberhard SPIESS and Michael TRENDELENBURG

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371©(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371 ©(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371©(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371©(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371©(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371©(5)).

**Items 11. to 16. below concern other document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:
  - (i) Sequence Listing (4 sheets)
  - (ii) Copy of unexecuted Declaration and Power of Attorney

|   |              |  |            |  |  |
|---|--------------|--|------------|--|--|
| U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50)<br><b>09/914397</b>   |              | INTERNATIONAL APPLICATION NO.<br>PCT/DE00/00116  |            | ATTORNEY'S DOCKET NUMBER<br>38485-0006   |  |
| 17. <input checked="" type="checkbox"/> The following fees are submitted:   |              |  |            | <b>CALCULATIONS</b> PTO USE ONLY   |  |
| <b>Basic National Fee (37 CFR 1.492(a)(1)-(5):</b><br>Neither international preliminary examination fee (CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... <b>\$1000.00</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... <b>\$860.00</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$710.00</b><br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... <b>\$690.00</b><br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... <b>\$100.00</b> |              |  |            |  |  |
| <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>   |              |  |            | <b>\$860.00</b>  |  |
| Surcharge of \$130.00 for furnishing the oath or declaration later than 20 ____ 30 ____ months from the earliest claimed priority date (37 CFR 1.492(e))  |              |  |            | \$   |  |
| CLAIMS  | NUMBER FILED | NUMBER EXTRA   | RATE       |  |  |
| Total Claims  | 10 -20 =     |  | X \$18.00  | \$   |  |
| Independent Claims  | 1 -3 =       |  | X \$80.00  | \$   |  |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable)   |              |  | + \$270.00 | \$   |  |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>  |              |  |            | <b>\$860.00</b>  |  |
| Applicants claim small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.   |              |  |            | \$   |  |
| <b>SUBTOTAL =</b>   |              |  |            | <b>\$860.00</b>  |  |
| Processing fee of \$130.00 for furnishing English translation later than 20 ____ 30 ____ months from the earliest claimed priority date (37 CFR 1.492(f)).  |              |  |            | +  |  |
| <b>TOTAL NATIONAL FEE =</b>   |              |  |            | <b>\$860.00</b>  |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +   |              |  |            | \$   |  |
| <b>TOTAL FEES ENCLOSED =</b>  |              |  |            | <b>\$860.00</b>  |  |
|   |              |  |            | Amount to be:  |  |
|   |              |  |            | refunded \$  |  |
|   |              |  |            | charged: \$  |  |
| a. <input checked="" type="checkbox"/> A check in the amount of <b>\$860.00</b> to cover the above fees is enclosed.<br>b. ____ Please charge my Deposit Account No. <u>08-1641</u> in the amount of \$ ____ to the above fees. A duplicate copy of this sheet is enclosed.<br>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-1641</u> . A duplicate copy of this sheet is enclosed.  |              |  |            |  |  |
| <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>  |              |  |            |  |  |
| SEND ALL CORRESPONDENCE TO:<br><b>Customer ID No. 26633</b><br>Colin G. Sandercock<br>HELLER EHRMAN WHITE & MCAULIFFE, LLP<br>1666 K Street, NW, Suite 300<br>Washington, DC 20006<br>Tel: (202) 912-2000<br>Fax: (202) 912-2020  |              |  |            |  |  |
|   |              | <br><b>26633</b><br>PATENT TRADEMARK OFFICE |            | <br>SIGNATURE<br>for NAME: COLIN G. SANDERCOCK<br>REGISTRATION NUMBER: 31,298<br>DATE: AUGUST 28, 2001 |  |

20010828 26633

|  |              |   |            |   |  |
|--|--------------|---|------------|---|--|
| U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50)  |              | INTERNATIONAL APPLICATION NO.<br>PCT/DE00/00116 |            | ATTORNEY'S DOCKET NUMBER<br>38485-0006  |  |
| 17. <input type="checkbox"/> The following fees are submitted:   |              |   |            | <b>CALCULATIONS</b> <span style="float: right;">PTO USE ONLY</span>                               |  |
| <b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b><br>Neither international preliminary examination fee (CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... <b>\$1040.00</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... <b>\$890.00</b><br><br>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$740.00</b><br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... <b>\$710.00</b><br><br>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... <b>\$100.00</b> |              |   |            |   |  |
| <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>  |              |   |            | \$  |  |
| Surcharge of \$130.00 for furnishing the oath or declaration later than 20 ____ 30 <u>X</u> months from the earliest claimed priority date (37 CFR 1.492(e))   |              |   |            | \$130.00  |  |
| CLAIMS   | NUMBER FILED | NUMBER EXTRA                                    | RATE       |   |  |
| Total Claims   | 13 - 20 =    | 0   | X \$18.00  | \$  |  |
| Independent Claims   | 2 - 3 =      | 0   | X \$84.00  | \$  |  |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable)  |              |   | + \$280.00 | \$  |  |
| <b>TOTAL OF ABOVE CALCULATIONS =</b>   |              |   |            | <b>\$130.00</b>   |  |
| <u>X</u> Applicants claim small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.   |              |   |            | \$ 65.00  |  |
| <b>SUBTOTAL =</b>  |              |   |            | <b>\$ 65.00</b>   |  |
| Processing fee of \$130.00 for furnishing English translation later than 20 ____ 30 <u>X</u> months from the earliest claimed priority date (37 CFR 1.492(f)).   |              |   |            | + \$130.00  |  |
| <b>TOTAL NATIONAL FEE =</b>  |              |   |            | <b>\$195.00</b>   |  |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +  |              |   |            | \$ 40.00  |  |
| <b>TOTAL FEES ENCLOSED =</b>   |              |   |            | <b>\$235.00</b>   |  |
| 03/06/2002 <b>NGUYEN</b>   |              | 00000056 09914397                               |            | Amount to be:   |  |
| 01 FC:254  |              | 65.00 OP  |            | refunded \$   |  |
| 02 FC:156  |              | 130.00 OP                                       |            | charged: \$   |  |
| a. <u>X</u> A check in the amount of <u>\$235.00</u> to cover the above fees is enclosed.<br>b. ____ Please charge my Deposit Account No. <u>08-1641</u> in the amount of \$ ____ to the above fees. A duplicate copy of this sheet is enclosed.<br>c. <u>X</u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>08-1641</u> . A duplicate copy of this sheet is enclosed.   |              |   |            |   |  |
| <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>   |              |   |            |   |  |
| SEND ALL CORRESPONDENCE TO:<br><b>Customer ID No. 26633</b><br><b>Colin G. Sandercock</b><br><b>HELLER EHRMAN WHITE &amp; MCAULIFFE, LLP</b><br>1666 K Street, NW, Suite 300<br>Washington, DC 20006<br>Tel: (202) 912-2000<br>Fax: (202) 912-2020   |              |   |            |   |  |
|  |              |   |            | <br>SIGNATURE |  |
|  |              |   |            | NAME: COLIN G. SANDERCOCK   |  |
|  |              |   |            | REGISTRATION NUMBER: 31,298   |  |
|  |              |   |            | DATE: MARCH 1, 2002   |  |

NOTED 457460

PTO/PCT Rec'd 1 MAR 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO. 38485-0006

In re patent application of: Sabine BUB *et al.*

Confirmation No.:

Serial No.: 09/914,397

Art Unit: Unassigned

Filed: August 28, 2001

Examiner: Unassigned

For: MOLECULAR-BIOLOGICAL MARKER FOR ANALYTICAL ELECTRON  
MICROSCOPY

**PRELIMINARY AMENDMENT**

Commissioner of Patents  
Washington, DC 20231

Dear Sir:

Prior to examination, please amend the above-identified application as set forth below. A marked-up copy of the amended claims is attached.

**In the Claims:**

Amend claims 1-10 as follows:

1. (amended) A plasmid comprising a vector pBluescript KS(+) derivative, wherein the vector contains more than 1 repetitive SK primer sequence element.
2. (amended) The plasmid of claim 1, wherein the vector pBluescript KS(+) derivative comprises 2, 7, 14, 21 or 27 repetitive SK primer sequence elements.
3. (amended) The plasmid of claim 1, wherein the primer sequence elements comprise a marker complex.

4. (amended) The plasmid of claim 1, wherein the SK primer sequence element comprises the sequence (SEQ ID NO: 5):

5' - GATCCACTAGTTCTAGAGCG-3'.

5. (amended) The plasmid of claim 1 wherein SK oligonucleotides with end modification can be bound thereto by a detectable element that is detectable by electron microscopy.

6. (amended) The plasmid of claim 5, wherein the detectable element is selected from the group consisting of boron, silicon, iron and manganese.

7. (amended) A method of analytical electron microscopy comprising the step of adding the plasmid of claim 1.

8. (amended) A host cell transformed with the plasmid of claim 1.

9. (amended) The host cell of claim 8, wherein the host cell is *E. coli* JM110.

10. (amended) A test kit for use in electron microscopy comprising:

- host *E. coli* JM110 bacterial cells suitable for replicating the plasmid of claim 1;
- and
- a single-stranded plasmid comprising 2x, 7x, 14x, 21x and 27x repetitive SK primer sequence elements.

**Add the following claims:**

-- 11. (new) The host cell of claim 8, wherein the cell is *E. coli*.

12. (new) A reagent for electron microscopy comprising pBluescript KS(+) derivative; and a SK oligonucleotide with end modification by a detectable element, wherein the element is detectable by electron microscopy.

13. (new) The reagent of claim 12, wherein the detectable element is selected from the group consisting of boron, silicon, iron and manganese.--


**REMARKS**

Applicants respectfully request entry of the foregoing amendments prior to examination. The amendments are presented to remove multiple dependencies, correct informalities, and clarify claim language. No new terms have been added to the claims. A first office action on the merits is awaited.

Please direct all correspondence to the undersigned attorney at the address indicated below.

2/28/02  
Date

Respectfully submitted,

  
Colin G. Sandercock  
Attorney for Applicant  
Reg. No. 31,298

**Customer No. 26633**  
HELLER EHRMAN WHITE & McAULIFFE LLP  
1666 K Street, N.W.  
Suite 300  
Washington, D.C. 20006  
Tel: 202-912-2000  
Fax: 202-912-2020



26633

PATENT TRADEMARK OFFICE

**MARKED UP VERSION OF AMENDED CLAIMS**

**Amend claims 1-10 as follows:**

1. (amended) A plasmid comprising a vector[, characterized in that it is derived from] pBluescript KS(+) derivative, wherein the vector [and] contains more than 1 repetitive SK primer sequence element.

2. (amended) The plasmid [according to] of claim 1, wherein the vector pBluescript KS(+) derivative [characterized in that it contains] comprises 2, 7, 14, 21 or 27 repetitive SK primer sequence elements.

3. (amended) The plasmid [according to] of claim 1 [ or 2], wherein [characterized in that] the primer sequence elements [carry] comprise a marker complex.

4. (amended) The plasmid [according to any] of claim[s] 1 [ to 3], wherein [characterized in that] the SK primer sequence element comprises the [following] sequence (SEQ ID NO: 5):

5' - GATCCACTAGTTCTAGAGCG-3'.

5. (amended) The plasmid [according to any] of claim[s] 1 [ to 4], wherein [characterized in that] SK oligonucleotides with end modification can be bound thereto[, which are modified at their ends] by a[n] detectable element that is detectable [under the] by electron microscop[e]y.

6. (amended) The plasmid [according to] of claim 5, wherein [characterized in that] the detectable element[s are] is selected from the group consisting of boron, silicon, iron [or] and manganese.

7. (amended) A method of analytical electron microscopy comprising [Use of a] the step of adding the plasmid [according to any] of claim[s] 1[ to 6 in analytical electron microscopy].

8. (amended) A host cell [*E. coli* cells] transformed with [a] the plasmid [according to any] of claim[s] 1[ to 6].

9. (amended) The host cell of [*E. coli* cells according to] claim 8, wherein [characterized in that] the host cell is *E. coli* JM110[ is concerned].

10. (amended) A test kit for use in electron microscopy[,] comprising[ at least the following components]:

- [competent]host *E. coli* JM110 bacterial cells suitable for [replication of a] replicating the plasmid [according to any] of claim[s] 1 [to 5,]; and
- a single-stranded plasmid[s] comprising 2x, 7x, 14x, 21x and 27x repetitive SK primer sequence elements.



PTO/PCT Rec'd 1 MAR 2002

09/914397

Molecular-Biological Marker for Analytical Electron  
Microscopy

The invention relates to a series of new plasmids on the basis of pBluescript KS(+), comprising more than 1 SK primer sequence element, preferably 2, 7, 14, 21 and 27 repetitive SK primer sequence elements, and the use thereof as a molecular-biological marker for analytical electron microscopy.

Electron spectroscopic imaging (ESI) is a method of analytical electron microscopy (EM), which pictures the distribution of a certain chemical element within the analyzed preparation. In order to elucidate the structural organizations of biological systems, it must be possible to optically differentiate the individual macromolecular components. At present, the charging with gold particles or other particles, which are visible in the refraction contrast, is used to label macromolecules for electron microscopy.

Thus far, multiple labeling experiments have been carried out in electron microscopy by using gold grains of various sizes to be able to differentiate the different target structures in a single preparation. For example, one molecule type would be linked to gold grains having a size of 5 nm while the other would be attached to those having a size of 10-20 nm in a double labeling experiment to ensure that in a subsequent evaluation the different molecules can clearly be localized and distinguished from one another.

09/914397

Large gold grains (larger than 10 nm) are disadvantageous because they have reduced penetration capacity into the tissue and reduced coupling efficiency to the target molecule (Giberson, T.R., and Demaree, R.S.: The influence of immunogold particle size on labeling density. Microscopy Research and Technique, 27, 355-357, 1994). In addition, such a large structure can no longer be assigned clearly to the site of binding to the target structure, i.e. resolution capability is lost. If a triple labeling experiment was aimed at, these drawbacks would become particularly striking. Only what is called ferritin molecules, i.e. large protein units which contain hundreds of iron atoms in their centers and can be linked to target structures, are an alternative to the gold grains. However, their electron density and thus their detectability under the transmission electron microscope is very poor so that their use has only proved feasible in rare cases.

In contrast thereto, florescence methods which enable triple labeling, and even quadruple labeling, without causing major problems have existed in the field of optical microscopy for some time now. Since as regards the labeling techniques electron microscopy cannot compete with optical microscopy for the time being, scientists are satisfied with the comparatively poor resolution capability of optical microscopes before they accept the drawbacks accompanying the labeling technology in the electron-microscopic field. The development of alternative labeling techniques for gold labeling would render electron microscopy more attractive because its competitiveness as regards labeling would be accompanied by a resolution capability over 100 times as good as that of optical microscopy. As an alternative to the labeling method using gold for the conventional transmission electron microscopy, which is based on the electron density

0944397 1030102

of the heavy metal gold, there is a demand for labeling methods for ESI. This technique utilizes interactions between beam electrons and the atoms in the preparation differing from those of conventional transmission electron microscopy. In principle, all of the elements can be detected specifically. This raises the number of elements in consideration for labeling methods. However, to establish alternative labeling methods it is decisive to check detection limits for the elements in consideration. This means in concrete terms that information is required on the number of detectable element atoms per  $\text{nm}^2$  area in the preparation. Thus, the detection limits of the ESI technique are relevant. Thus far, there are only some studies and vague indications on this parameter. Although the ESI technique is often used, no data on detection limits have been published to date.

There is thus a demand for alternative labeling methods for electron microscopy. It should be possible to readily test and assess the detectability of such a marker complex.

It is thus the object of the present invention to provide a possibility of obtaining data by means of which it is possible to evaluate the prospects of the intended experiment with the element in question and/or the marker structure in question before time-consuming cytobiological and molecular-biological experiments are carried out. Furthermore, the parameter for the detectable number of elementary atoms per unit area shall become measurable to obtain therefrom the information necessary to establish EM labeling methods.

This object is achieved by the subject matters defined in the attached claims.

20250726 14:39:00

The reason why the above-mentioned preliminary tests are necessary is that thus far no accurate limiting values of detectability have been known for the ESI detection of the various chemical elements. This is *inter alia* due to the fact that preparing a suitable test sample is not a trivial matter. Such a sample must have special properties. There must be regions in which the target element is available in a clearly defined amount. It must be possible to clearly detect these regions. The target element may not occur in the remaining regions. This problem can be shown by means of the publication by Golla, U. and Kohl, H. (Micron, 28 (5), 397-406, 1997) who using uranium as an example tried to document the resolution and detectability by means of grainy precipitates.

According to the invention a series of new plasmids having more than 1, preferably 2, 7, 14, 21 and 27, SK primer sequence elements, was produced in direct head/tail-oriented repetition on the basis of pBluescript KS(+). The annularly closed plasmid is available as a target structure which contains repetitively a short DNA sequence (SK primer sequence element). The SK primer sequence element comprises the following sequence:

5'-GATCCACTAGTTCTAGAGCG-3'.

The SK primer sequence represents a segment of 20 nucleotides which is referred to as such by the company of Stratagene in the vectors pBluescript KS(+/-) and Bluescript SK (+/-) and lies within the "multiple cloning site" (MCS). pBluescript is a plasmid vector sold by Stratagene. It is an annular DNA molecule which contains the genetic information necessary for replication in *E. coli*. The multiple cloning

site (MCS) is decisive for cloning foreign DNA segments into this vector. According to the invention the above-mentioned SK primer sequence repetitions were incorporated into this MCS region so that the resulting plasmids of pBluescript only differ as regards the MCS, i.e. are derived from pBluescript.

A homologous sequence may be bound to this repetitive sequence by means of hybridization. In case this hybridizing sequence carries a marker complex, the marker will reach the target structure by hybridization.

The hybridizing sequence, hereinafter referred to as SK oligonucleotide or SKO, can be modified chemically at its ends to permit a covalent bond of different markers. As a result, it is possible to study any labeling strategies. A molecule can be linked to the SKO containing an element in the highest possible concentration which shall be tested for usability as a marker for ESI. Boron markers as described in German patent application 198 03 206.4, for example, are suited. Further promising markers are silicon as well as iron and manganese. The marker compound is built up in a controlled synthesis such that the number of target elementary atoms is known and the target element is present in the greatest possible amount in the center of the marker compound. It can also be linked to the SKO as a unit. In order to meet these demands, e.g. the boron marker structure is synthesized by treating it like a nucleoside unit in the oligonucleotide synthesis. Thus, the preferred linking system provides the production of a boron compound containing the necessary protective groups and linkage groups for the oligonucleotide synthesis according to the phosphoramidite method, in the course of which an oligonucleotide is built up, building block by building

09044397-030102

block, from the 3' end to the 5' end. In this connection, there is the possibility that for this purpose the boron complex is attached as such or in the form of a 5'-boron nucleotide(C)-3' building block to the 5' end of SKO in the last step (see in this connection also German patent application 19803206.4). It is advantageous for the marker-containing building block to contain a spacer which will cause the marker complex to stand off from the SKO so as not to impede the hybridization of the labeled SKO with the complementary plasmid regions. Aliphatic hydrocarbon chains which have lengths between  $C_2$  and  $C_{10}$  and may possibly contain oxygen groups in the form of ether bridges (preferably a maximum of 5 bridges) are in consideration as spacers (see in this connection also German patent application 198 03 206.4). A similar procedure can be used for any other marker structures, each containing another target element.

The labeled oligonucleotides are hybridized to the DNA and are present selectively in the preparation at the sites where the annular DNA molecules are located. Depending on the repetition degree of the SK elements on the employed plasmid molecules, variable but defined amounts of target elementary atoms will thus be attached to the DNA in a very close arrangement. Therefore, densest packaging can be assumed because it was found that the distances of the marker structures on the DNA are 8 nm. This follows from a calculation of the extension of double-stranded DNA regions over the SK repetition units present in the plasmids. Since the marker structure will have a maximum diameter of 5 nm there is in fact some space available between the markers. However, this space should be maintained because the hydrate envelope of the marker compounds must be taken into account.

09944397-030402

The plasmid according to the invention is prepared on the carrier matrix of the sample holder for ESI in spread form. The above plasmids enable the preparation of single-stranded annular plasmid DNA molecules after infecting plasmid-containing *E. coli* cells, preferably *E. coli* JM 110, by means of what is called a helper virus. The (+) sign in the name of the original plasmid pBluescript KS (+) indicates that only the plus strand of the plasmid molecule is isolated. A single-stranded DNA sample is now available against which complementary DNA regions can readily be hybridized without the otherwise necessary fusing of the DNA duplex. In order to hybridize SK oligonucleotides (SKO) complementary with the plus strand of the plasmids, they must, of course, represent the sequence of the minus strand, i.e. 5'-CGCTCTAGAACTAGTGGATC-3'. Such an oligonucleotide can be produced by means of automatic oligonucleotide synthesis. These molecules are mixed in an aqueous solution with one of the above-mentioned single-stranded plasmid molecules. Double-stranded regions form at the sites where the SK oligonucleotides (SKO) have found the complementary partner on the singled-stranded DNA, i.e. SK oligonucleotide/plasmid hybrids (hereinafter referred to as SKOPH). In order not to impede the binding of the single SKOs to the DNA, a gap of 4 nucleotides is preferably provided as a spacer between the SK oligonucleotide binding sites.

Theses SKOPHs are preferably separated by the chromatography of unbound SKOs. This may be done by column chromatography, e.g. Amersham Pharmacia Biotech (Freiburg, Germany) offer column matrixes (e.g. sephadex or sepharose). The purified SKOPHs are then subjected to spreading. In this connection otherwise coiled DNA molecules are pretreated such that they are stretched in solution and in this state are applied onto electron-microscopic small carrier nets coated with a thin

091437-030102

sheeting, made visible by treatment with heavy metals and analyzed under a transmission electron microscope (TEM). If ESI analysis shall be carried out, heavy metal treatment should be dropped, since every element occurring in high amounts and/or high concentrations in the preparation interferes with, or makes impossible, the specific detection of the target element. The DNA rings are then distributed uniformly over the surface of the TEM preparation and are separate from one another. The above-mentioned basic preconditions are thus met: the annular DNA is clearly evident, the SKOs are available in a more or less large number and are bound to the DNA, and there is (almost) nothing between the DNA regions.

In case it is not clear whether the SKOs were bound to the repetitive region, there are two possibilities for control: a) SKOs labeled at the 5' position by digoxigenin or biotin are used against which an anti-digoxigenin or an anti-biotin antibody is employed which itself is labeled with gold and can be detected by conventional TEM. The size of the gold grains may, however, not exceed a diameter of about 6 nm (otherwise the gold grains could interfere with one another); b) the repetitive target plasmid can be linearized, possibly in combination with a), by restriction endonuclease digest along with the repetitive SK region, so that following spreading the binding sites of the SKOs are readily identifiable in that they must be located at the end of a thread-like DNA molecule. Since restriction endonucleases only excise double-stranded DNA, its restriction site must first be made double-stranded by hybridization of an oligonucleotide complementary around the restriction site.

09044397 030102



The repetitive sequences are arranged closely one behind the other and extend over about a third of the plasmid. These repetitive sequences render the test much more significant. The advantage of the above described plasmids consists in that 1 to 27 of the marker units can be accumulated so as to modulate the number of marker elementary atoms. When it is possible to show the labeled SKOPHS in differing spreading states from fully extended to coiled in the spreading preparation, the target elementary atoms, bound particularly to coiled DNA molecules, can i) be concentrated within a very confined space, ii) become localizable due to the uniformly fibrillary ring shape of the DNA bound thereto, iii) be analyzed in defined but variable number, and iv) in an otherwise element-free environment.

DNA segments outside the repetition regions to which no marker can bind serve as a negative control for the ESI elemental detection. Such a negative control is necessary because the specificity of a calculated target element distribution could be doubted if there was no comparative region without target element and correspondingly without calculated element signal. Since the test represents a molecular-biological system, the marker is assessed in its physico-chemical environment. This also means that the test is very close to a medical/biological application, in particular the *in situ* hybridization.

It is the objective of this test method to obtain reliable data on the minimum number of target element atoms per unit area necessary for ESI detection. At the same time, data are obtained on the individual detectability of the marker structure because due to the repetition thereof it is also possible to average weak element-specific signals, in particular in DNA molecules available in the electron-

09944397 030102

microscopic preparation in a fully stretched manner. Thus, it can already be determined prior to a technically complicated use of a marker structure in medicine or biology whether optionally the number or/and the concentration of the target elementary atoms must still be increased in the marker structure. As experience shows, all of the plasmid states from stretched to considerably coiled are found in spreading preparations, in particular when the spreading process did not proceed in optimum fashion. This usually undesired case is of advantage in connection with the explained determination of elemental detection limit.

Many variations of spreading methods are found in the literature (regarding a summary see: Electron Microscopy in Molecular Biology; a practical approach, Sommerville, J. and Scheer, U. (eds.), IRL Press, 1987).

The threshold values for the element-specific detection can be determined by the standard methods of elemental detection using ESI. For this, there is presently no other method. It can thus be imagined that this method is also of interest for the scientists who do not have in mind a biologically/medical use but are interested in the detection limits of any chemical elements other than those mentioned above. The precondition is that the target element is already present in the marker structure linked to the oligonucleotide in the highest possible concentration and in the greatest possible amount.

The use for ESI has been specified above. In addition, applications of parts of the test system are also possible which go beyond the use in electron microscopy. Two further sample applications are mentioned here briefly and specified below: 1) the SK primer repetition cassette can generally be

0914397-030400

utilized for the efficient and localized DNA labeling by hybridizing labeled oligonucleotides; 2) for studying the mechanisms of deleting direct repetitions in DNA the below described plasmids form the model substrate.

In addition to the application in the field of electron microscopy, said repetition regions enable, as stated above, the possibility of also rendering DNA quite generally detectable after the hybridization by means of the SKO-linked markers which are still below the detection limit as single molecules but can be identified in repetitive arrangement. For this purpose, the repetition regions can also be recloned into the desired DNA molecules via SAC I/Kpn I-compatible ends. For example, the route of DNA can then be tracked by such a method after introduction into a cell (transfection). Here, the uses of both optical and electron microscopes are in consideration.

The chemical modifiability of the hybridizing sequence permits different uses of the test for differently configured marker units. Since the test represents a molecular-biological system, the marker is assessed in its physico-chemical environment. The individual detectability of the marker is analyzed. The intensity of weak signals can be determined precisely by averaging.

The following statements made on the production of the plasmids containing different repetitions show that in principle the repetition steps (pBluescript KS (+)) 2x, 3x, 4x, 5x, 6x, 7x, 14x, 21x and 27x SK are available for the experiments for the actual elemental detection for ESI. Since the analysis of differences as to the detectability of the target element using ESI will be especially convincing when the number of analyzed elementary atoms varies

09944397 030103

considerably (see in this connection the below statements), the repetition degrees 2x, 7x, 21x and 27x SK are of special interest.

As mentioned above, the present invention is based on the fact that a test preparation contains areas in which the target element is available in a clearly defined amount and can be detected unambiguously. The target element may not occur in the remaining areas.

The plasmid construction is stabilized by introduction into a *dam*<sup>-</sup>/*dcm*<sup>-</sup> strain (preferably *E. coli* JM 110). JM110 is *dam*<sup>-</sup>/*dcm*<sup>-</sup> and contains no other striking genotypic markers which would clearly distinguish this strain from the other ones used, so that they can be employed as well. The repetitive plasmids according to the invention are introduced into the *dam*<sup>-</sup>/*dcm*<sup>-</sup> strain according to standard methods (cf. Sambrook, J., Fritsch, E.F. and Maniatis, T.: Molecular cloning; A laboratory manual; Second edition, Cold Spring Harbor Laboratory Press (1989)). Surprisingly, a deletion of the directly repetitive elements is thus avoided during bacterial replication. It is actually known that direct repeats or inverted repeats are lost during the replication in *E. coli*. *dam*/*dcm* strains are documented in the literature (cf. Marinus et al., J. Bacteriol. 114 (3), 1143-1150 (1973)); however, stabilization of directly repetitive sequences, resulting therefrom, has never been described.

The repetition degree could even be increased to 27x in *E. coli* JM110. Furthermore, the combination of *E. coli* JM110/pB1 KS (+) 27xSK is for the first time a system in which a direct repetition sequence otherwise unstable in *E. coli* can be replicated. Bacterial geneticists get the

09944397 030403

possibility of analyzing the underlying mechanisms of this type of deletions in bacteria and characterize the involved components. The question of stabilizing repetitions of such a type in *E. coli* is of interest e.g. for cloning specialists who try to obtain human DNA segments in their original state even if they had been replicated in *E. coli* (see e.g. human genome project). The background is that human DNA segments also contain short directly repetitive segments which like the above-described SK primer sequence repetition can show relatively poor stabilizing characteristics.

The plasmids according to the invention can be combined into test kits for use in electron microscopy. A test kit contains e.g. the following materials: 1) competent *E. coli* JM110 bacterial cells for replicating the repetitive plasmids; 2) the single-stranded plasmids 1x or 2x, 7x, 14x, 21x and 27x SK for the differential analysis of marker structures for the electron microscope; 3) electron-microscopic small carrier nets which are already coated for spreading; 4) SK oligonucleotides labeled at their 5' end by biotinylation or digoxigenation and serving for optimizing hybridization and spreading by proving by means of a gold-linked anti-biotin or anti-digoxigenin antibody that the repetitive arrangement is actually given on the plasmid; 5) instructions describing the individual processing steps. If there is an interest in applications other than the ESI-dependent ones, the test kit can be modified for those interested.

The plasmids having 2, 7, 14, 21 and 27 SK primer sequence elements were deposited as *E. coli* cultures with DSMZ (*Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH*) [German-type collection of microorganisms and cell

0944397-030103

cultures], Mascheroder Weg 1, Braunschweig, Germany, under accession numbers DSM 12600, DSM 12601, DSM 12602, DSM 12603, and DSM 12604 on December 22, 1998:

|                |           |
|----------------|-----------|
| pBI KS(+)2xSK  | DSM 12600 |
| pBI KS(+)7xSK  | DSM 12601 |
| pBI KS(+)14xSK | DSM 12602 |
| pBI KS(+)21xSK | DSM 12603 |
| pBI KS(+)27xSK | DSM 12604 |

The following figures explain the invention in more detail.

**Figure 1: Outline of the production of pBI KS(+) 2x SK.**

The kind of presentation given here is continued in the following illustrations of this kind. The multiple cloning site (MCS) is shown as a dark-gray block, and the SK primer sequence included therein is light gray. The restriction sites are marked by a finely broken line. The detailed sequence is indicated by the segments important for cloning.

- a) Diagram of pBI KS(+). pBI KS(+) was digested with the restriction enzymes Kpn I and BamH I for subsequent cloning. The restriction sites are marked by a finely broken line. The MS fragment therebetween falls out.
- b) Diagram of pBI KS(+) digested with BamH I and Kpn I and the SK-PH I fragment which should result in pBI KS(+) 2x SK by ligation with pBI KS(+). Part of MCS was excised by digest with Kpn I and BamH I (see also a), and the fragment SK-PH I was inserted in return. Using SK-PH I the previously present Bam H I restriction site was masked by means of modification of a base pair (bold letters) and a new BamH I restriction site was introduced at the same time. Due to the different

201000-262460

restriction sites (Kpn I/BamH I) the fragment can only be cloned in a possible orientation. The restriction site Pvu I served as a control restriction site for the successful incorporation of the insert SK-PH I (no further data shown in this connection).

- c) Diagram of pBl KS(+) 2x SK. pBl KS(+) 2x SK was formed by ligation of SK-PH I with the BamH I/Kpn I digested pBl KS(+) (cf. b). The modified BamH I restriction site marked by an asterisk could no longer be excised by BamH I. In order to simplify the following text, the region marked in the illustration (SK primer + non-hybridizing sequence) is marked by a black arrow. This leads to the schematic plan for pBl KS(+) 2x SK as shown under item d).
- d) Simplified presentation of pBl KS(+) 2x SK. The full black line stands for MCS, the broken line stands for the remaining vector pBl KS(+). The black arrows show the 5' → 3' direction of the cloned SK primers plus 4 bp sequence not to be hybridized (cf. item c).

**Figure 2: simplified diagram of pBl KS(+) 7x SK.**

The pBl vector is marked by a broken black line; seven SK primer sequences are now contained in its Kpn I/Sac I-oriented MCS. The SK-PH II fragment (dashed arrow on the top and sequence "SK-PH II" emphasized by lines at the bottom) inserted the seventh SK primer and the additional Eag I restriction site in the vector. The important sequences are emphasized in detail. The SK primer sequence is light gray, the rest of MCS and the 4 base spacers are dark gray. The restriction sites are marked in the sequence by a finely broken black line.

090497-020102

### Figure 3: Diagram of cloning a pBl2x block plasmid

- a) Insertion of a 7x SK block in the Not I-opened pBl 1x block DNA. The characterization of the individual components is identical with those of figure 1 or figure 2. The clone pBl 1x block was linearized with the Not I enzyme and ligated with the PCR fragment subsequently cut by Eag I beforehand. In order to simplify the following text, the seven SK fragments are combined into a gray arrow.
- b) Presentation of the transitions between individual blocks. The marking of the components can be compared with that in figure 1.a-d. By ligation of the 7x SK block (gray arrow) in the proper orientation, the Not I restriction site which opened the pBl 1x block beforehand was masked by the 5' end of the newly added 7x SK block (bold letters) and could no longer be excised by Not I. The 3' end of the fragment completes the Not I restriction site towards the vector. As a result, it is possible in the next cloning run to again linearize the pBl 2x block with Not I without losing the 14 SK primer. In contrast to the BamH I cleavage site between the individual SK primers in the block (BamH I\*), the BamH I restriction site at the 5' end of a 7x block is maintained (BamH I) and can subsequently be used as an orientation control.

### Figure 4: Sequencing result of the plasmid construct containing 27 SK primer elements

Black bars mark the SK primer sequence regions in the repetitive region sequenced from both sides. Sequences ATCT or GCCG which have a length of 4 base pairs are located between these SK primer sequence regions for reasons of cloning technique.

0944397.03010  
2010E0 2647650



## Figure 5: Diagram of the labeling experiment

The following example explains the invention in more detail.

### Example

The below described methods of producing the plasmids containing the repetitions are described in Sambrook, J., Fritsch, E.F. and Maniatis, T. (Molecular cloning; a laboratory manual; second edition; Cold Spring Harbor Laboratory Press, 1989) and in Current Protocols in Molecular Biology (John Wiley and Sons, 1994-1998), the below techniques, such as DNA replication, restriction endonuclease digest, ligation, agarose gel electrophoresis, and PCR being sufficiently known to, and mastered by, a person skilled in the art.

The SK primer element of Bluescript was selected for the repetition (Stratagene company, Heidelberg, Germany) because it does not contain any self-complementary or homooligomeric regions, with a G/C content of 50 % it lies within the average region of natural DNA and is suited for the almost full production of directly repetitive regions as regards the cloning technique. Furthermore, it is advantageous that this region hybridizes reliably and stably with a complementary sequencing primer (identical with the SK primer described herein) since it has been designed by Stratagene (Heidelberg) as a sequencing primer binding site.

A short oligonucleotide fragment is required for the construction of SK primer sequence elements in repetitive succession. It contains the SK primer sequence and restriction sites for carrying out cloning. For this purpose oligonucleotides complementary to one another were

093449.0300

synthesized. These ss-DNA fragments were converted by hybridization into clonable ds fragments by juxtaposing the two complementary oligonucleotides in equimolar fashion in 10 mM Tris buffer. Accomplished cloning is a control for the success. The resulting fragments were referred to as SK-PH I (SK primer hybrid I; fragment which was used for the SK primer replication of 2 - 6 SK primer sequences; see Ill. 1) and SK-PH II (SK primer hybrid II; fragment which introduced the seventh SK primer and the Eag I restriction site; see Ill. 2).

For the production of the plasmid pBl KS(+) (pBluescript KS(+)) with two SK primers (pBl KS(+) 2x SK), the pBl KS(+) had to be opened using BamH I and Kpn I, part of the multiple cloning site MCS having been removed (Ill. 1a). The complete double digest was identified on a 2 % agarose gel, followed by ethanol precipitation. The insert SK-PH 1 (Ill. 1b) was added to the opened vector for ligation in a tenfold excess (see Ill. 1b). This high excess could be justified since the 5' ends of the fragment were not phosphorylated, i.e. oligomers of the inserts could not form. The transformation in *E. coli*, e.g. XL1-Blue, was carried out using this ligation batch. Of the raised colonies the plasmid DNA was isolated by mini-preparation from three clones for cloning control. The resulting clones are indicated below as pBl KS(+) 2x SK (Ill. 1c).

The further cloning of plasmids with up to seven SK elements contained in equal orientation was time-consuming, since one clone from the last cloning run served in each case as a basis for the next cloning step. Correspondingly, the midi-prep-DNA of the select pBl 2x SK clone was again double-digested by BamH I/Kpn I and admixed with SK-PH I, ligated and transformed in *E. coli* XL1-Blue. Contrary to the

09944397-03010

strategy used for cloning pBl 2x SK, attention had then to be paid especially to an efficient double digest using BamH I and Kpn I. As shown in Ill. 1c, the restriction sites into which another SK-PH I fragment should be integrated, were only six base pairs apart from one another. Such a small distance between two restriction sites does not permit the simultaneous restriction of both restriction sites. Correspondingly, the restriction had to be carried out successively using the two enzymes. Cloning up to the plasmid pBl KS(+) 6x SK was carried out in this way.

Having cloned the seventh SK primer sequence, the repetitive elements were replicated block-wise. This could only function with a restriction site separating the region with seven SK primers as a unit from the vector. This was enabled by ligation of the SK-PH II (Ill. 2) in pBl 6x SK. Along with the seventh SK element, SK-PH II introduced the new restriction site Eag I into the vector. The seven SK primers were then confined by two Eag I restriction sites (Ill. 2) because the starting vector pBl KS(+) already had such a restriction site in the MCS.

In order to accelerate the further cloning steps, the block-wise replication of the SK elements was made by means of polymerase chain reaction (PCR). The plasmid preparation from XL1-Blue was taken as a template DNA for the amplification of the fragment with seven repetitive elements. It was derived directly from the original colony (pBl 7x SK). In a first optimization of the PCR it should be analyzed which primer pair amplified the target fragment having the best quality and quantity. The primers M13, M13 reverse, T3 and T7 (M13: TGTAACGACGGCCAGT; M13 reverse: CAGGAAACAGCTATGACC; T3: AATTAACCCTCACTAAAGGG; T7: TAATACGACTCACTATAGGG) were tested in various combinations.

094439 0307  
201002 2547660

All of these primers had their binding sites outside the MCS, either close to the  $\beta$ -galactosidase starting point or close to the T7 transcription starting point in pBluescript KS (+). PCR took place under standard conditions. The various batches contained the matching primers in the various combinations possible: M13/M13 reverse, T7/T3, T7/M13 reverse and T3/M13. All of the four primers were combined without the template in the negative control. Since the PCR batch supplied the best results with T3/T7, this primer pair was used for the PCR.

In order to be able to ligate the insert fragment obtained by means of PCR into the NotI-opened vector, it had to have sticky ends compatible with Not I. For this purpose, the PCR fragment which contained the seven SK primers had to be subsequently cut at the edges. The restriction enzyme Eag I shortened the 246 bp long PCR fragment whose edges closed the sequences of primers T3/T7 by 47 bp and by 51 bp on the other side. This difference with respect to the control could still be made visible using a 2.2 % gel. pBl KS(+) 7x SK changed into pBl KS(+) 14x SK in only one step using the PCR-amplified 7x SK fragment whose edges became compatible with Not I by Eag I digest. See Ill. 3 for an outline of the cloning manner. The digested fragment was purified prior to ligation by the PCR purification kit (Qiagen company). This should serve for removing the primers not consumed in the PCR reaction and the fragments resulting from the digest.

As compared to the first cloning steps which resulted in pBl KS(+) 7x SK, the vector was not opened by two different enzymes (Kpn I/BamH I; see Ill. 1) but linearized by Not I. Therefore, an accumulation of religations had to be expected. In this cloning, a religation could not be counteracted by an insert concentration increased many times

2091497.03040

over (7x SK fragment), since the DNA blocks were phosphorylated at their 5' ends and uncontrollable oligomerizations of the insert DNA had to be expected. Therefore, the religations were reduced, or even suppressed, by dephosphorylating the vector. The DNA referred to as pBlKS(+)-7xSK thus far is designated pBl 1xblock below.

The pBl 1x block opened by Not I was ligated with the purified PCR fragment which also contained seven SK primers. This was enabled by the single Not I restriction site located at the edge of the repetitive elements, by which the pBl 1x block was linearized. As mentioned above, the PCR fragment was subsequently cut with the Eag I enzyme compatible with Not I and ligated directly to the seven SK primers of the vector (pBl 2x block).

Since pBl 7x SK proved to be stable in the JM110 host strain, the ligation batch of the plasmid with 14 SK elements was also transformed into this strain. The transformation of pBl KS(+) 14x SK in JM110 yielded 118 transformants. This corresponded to a transformation rate of  $1.7 \times 10^3$  cfu (colony forming units)/  $\mu$ g DNA.

Step-wise replication was used, in this case with the aim of building up with the 7x SK blocks a plasmid having 28 repetitive SK primer sequences. For this, the pBl 2x block was linearized by Not I as shown analogously in Ill. 3. The full digest was examined on a 1 % agarose gel. The 5' ends of this Not I-opened plasmid were dephosphorylated and ligated with the 7x SK block. Seven colonies resulted from this transformation.

Control digest with BamH I of several candidate clones showed that a complete 7x SK block had additionally been

0944397 030400  
2010E0 2634T660

inserted. One of the clones was replicated for a midi preparation and the DNA was prepared. The sequence analysis from this midi preparation identified the complete and correct sequence of 21 SK primers including the functioning restriction sites which were required for the next cloning run. The gel analyses were confirmed in this connection. This clone is referred to as pBl 3x block below. It served as a precursor for the next insertion run.

In order to obtain a plasmid having 28 repetitive SK elements, the block-wise replication of the 7x SK block was continued. The pBl 3x block was used as a starting plasmid of this cloning. This cloning was treated like the two preceding ones. The pBl 3x block was linearized using Not I, checked for full digest in a 1 % agarose gel and then dephosphorylated. The dephosphorylated vector was used together with the PCR-amplified and subsequently cut 7x SK block in a ligation batch. The control ligation for evaluating the dephosphorylation yielded 2 clones. 59 clones formed in the transformation of the ligation with insert, 16 colonies of which were selected for a mini preparation. Separation with an agarose gel after Sac I/Kpn I digest was made as usual on a 2.2 % gel matrix.

A total of 5 clones had prolonged insert regions. Control digests with BamH I and triple digests with Sac I/Kpn I/BamH I showed fragment patterns indicating that no complete 7x SK block might have joined. A BamHI site must have been deleted in the newly joined block during the cloning instead.

One of the five equal clones was chosen and a sequence analysis was made using its midi-prepared DNA. Sequencing confirmed the result that the newly joined BamH I restriction site was deleted. The complete SK primer with

094439 0300  
"0000" 054466

intact BamHI restriction site of the last joined 7x SK block lacked. The result was thus a pBl KS(+) plasmid having 27x SK primers. The sequence of this clone is shown in figure 4.

094497 030400  
007050 064460

## Claims

- 1) A plasmid, characterized in that it is derived from pBluescript KS(+) and contains more than 1 repetitive SK primer sequence element.
- 2) The plasmid according to claim 1, characterized in that it contains 2, 7, 14, 21 or 27 repetitive SK primer sequence elements.
- 3) The plasmid according to claim 1 or 2, characterized in that the primer sequence elements carry a marker complex.
- 4) The plasmid according to any of claims 1 to 3, characterized in that the SK primer sequence element comprises the following sequence:  
  
5'-GATCCACTAGTTCTAGAGCG-3'.
- 5) The plasmid according to any of claims 1 to 4, characterized in that SK oligonucleotides can be bound thereto, which are modified at their ends by an element detectable under the electron microscope.
- 6) The plasmid according to claim 5, characterized in that the elements are selected from boron, silicon, iron or manganese.
- 7) Use of a plasmid according to any of claims 1 to 6 in analytical electron microscopy.
- 8) *E. coli* cells transformed with a plasmid according to any of claims 1 to 6.



- 9) *E. coli* cells according to claim 8, characterized in that *E. coli* JM110 is concerned.
- 10) A test kit for use in electron microscopy, comprising at least the following components:
- competent *E. coli* JM110 bacterial cells for replication of a plasmid according to any of claims 1 to 5,
  - single-stranded plasmids comprising 2x, 7x, 14x, 21x and 27x SK.

090439 03040  
207020 26E4650

### Abstract of the Disclosure

The invention relates to a plasmid which is characterized in that it is derived from pBluescript KS(+) and contains more than 1, preferably 2, 7, 14, 21 and 27, repetitive SK primer elements, and to the use thereof for analytical electron microscopy.

0944397 030403  
207020 26E4660

09/914397




Fig. 1a






Fig. 1b

Modified  
BamH I restriction site (BamH I\*)

09914397.030102



09/9/4397




Fig. 2

09/9/4397




Fig. 3a




Fig. 3b

09/9/4397

207000-4524760


-AGCTCGAAATTAACCCCTCACTAAAGGSAACAAAAGCTGGTACCGGCGGATCCACTAGTTCTAGAGCGATCTGATCCACT 80  
 TCGAGCTTTAATTGGGAGTGATTTCCCTTGTTTTCGACCATGCGCGGCTAGGTGATCAAGATCTCGCTAGACTAGGTGA  
  
 AGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAG 160  
 TCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATC  
  
 AGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGGCGGATCCACTAGTTCTAGAGCGATCT 240  
 TCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCGGCTAGGTGATCAAGATCTCGCTAGA  
  
 GATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACT 320  
 CTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGA  
  
 AGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGGCGGATCCACTAGTTCTAG 400  
 TCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCGGCTAGGTGATCAAGATC  
  
 AGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCT 480  
 TCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGA  
  
 GATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACT 560  
 CTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGA  
  
 AGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAG 640  
 TCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATC  
  
 AGCGATCTGATCCACTAGTTCTAGAGCGATCTGATCCACTAGTTCTAGAGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG 717  
 TCGCTAGACTAGGTGATCAAGATCTCGCTAGACTAGGTGATCAAGATCTCGCGGCGGCGGCGGCGGCGGCGGCGGCGGCGG

Fig. 4

09/9/4397


Diagram of the labeling experiment:

Outline:



Plasmid (blue) having 16 repetitive sequence to which the ESI marker (red) binds

Detail:



Spacer

The ESI marker (red) is covalently bonded to a single-stranded oligonucleotide (green). The oligonucleotide is associated by complementary base pairing (hybridization) with the repetitive sequences of the plasmid (blue). In this example, the repetitive sequences have a length of 20 nucleotides and are separated by a spacer of 4 nucleotides.

Fig. 5



**DECLARATION AND POWER OF ATTORNEY**

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**MOLECULAR-BIOLOGICAL MARKER FOR ANALYTICAL ELECTRON MICROSCOPY**

the specification of which (check one)

\_\_\_ is attached hereto.

X was filed on January 7, 2000 as PCT International Application Number PCT/DE00/00116 and was amended on \_\_\_\_\_.

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of

any PCT international application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application Number | Country | Foreign Filing Date | Priority Claimed? | Certified Copy Attached? |
|----------------------------------|---------|---------------------|-------------------|--------------------------|
| 199 00 511.7                     | Germany | January 8, 1999     | Yes               | No                       |
|                                  |         |                     |                   |                          |
|                                  |         |                     |                   |                          |

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

| U.S. Provisional Application Number | Filing Date |
|-------------------------------------|-------------|
|                                     |             |
|                                     |             |
|                                     |             |

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

| U.S. Parent Application Number | PCT Parent Application Number | Parent Filing Date | Parent Patent Number |
|--------------------------------|-------------------------------|--------------------|----------------------|
|                                |                               |                    |                      |
|                                |                               |                    |                      |
|                                |                               |                    |                      |

I HEREBY APPOINT the following registered attorneys and agents of the law firm of **Heller Ehrman White & McAuliffe** to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith:

PAUL M. BOOTH  
PATRICIA D. GRANADOS  
JOHN P. ISACSON  
RONALD J. KAMIS  
MARVIN A. MOTSENBOCKER  
COLIN G. SANDERCOCK  
SUSAN E. SHAW MCBEE

Reg. No. ~~40,244~~  
Reg. No. ~~33,683~~  
Reg. No. ~~33,715~~  
Reg. No. ~~41,104~~  
Reg. No. ~~36,614~~  
Reg. No. ~~31,298~~  
Reg. No. ~~39,294~~

and I request that all correspondence be directed to:

~~Colin G. Sandercock, Esq.~~  
~~HELLER EHRMAN WHITE & MCAULIFFE~~  
~~1666 K Street, NW, Suite 300~~  
~~Washington, DC 20006~~  
 Telephone: (202) 912-2000  
 Facsimile: (202) 912-2020

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor Sabine BUB  
 Residence D-76661 Phillipsburg, Germany  
 Citizenship Germany  
 Post Office Address Birkenstrasse 37, D-76661 Phillipsburg, Germany  
 Inventor's signature S. Bub  
 Date 14. Dez. 01

Name of second inventor Helmut TROESTER  
 Residence D-68165 Mannheim, Germany  
 Citizenship Germany  
 Post Office Address Leibnitzstrasse 4, D-68165 Mannheim, Germany  
 Inventor's signature Helmut Troester  
 Date 15. Jan. 02

Name of third inventor

Karsten RICHTER

Residence

D-68775 Ketsch, Germany

Citizenship

Germany

Post Office Address

Veilchenweg 20, D-68775 Ketsch, Germany

Inventor's signature

*K. Richter*

Date

15. Jan. 02

Name of fourth inventor

Ansgar HAKING

Residence

D-69214 Eppelheim, Germany

Citizenship

Germany

Post Office Address

Hauptstrasse 60, D-69214 Eppelheim, Germany

Inventor's signature

*Ansgar Haking*

Date

15. Jan. 02

Name of fifth inventor

Stefan RADDATZ

Residence

D-69115 Heidelberg, Germany

Citizenship

Germany

Post Office Address

Woerthstrasse 5, D-69115 Heidelberg, Germany

Inventor's signature

*Stefan Raddatz*

Date

01/18/02

Name of sixth inventor

Manfred WIESSLER

Residence

D-67227 Frankenthal, Germany

Citizenship

Germany

Post Office Address

Wilhelm-Mayer-Strasse 2, D-67227 Frankenthal, Germany

Inventor's signature

*M. Wiessler*

Date

15. Jan. 02

7W  
Name of seventh inventor

Eberhard SPIESS

Residence

D-68526 Ladenburg, Germany *Duf*

Citizenship

Germany

Post Office Address

Stahlbuehling 15, D-68526 Ladenburg, Germany

Inventor's signature

*[Signature]*

Date

15 Jan 2002

8W  
Name of eighth inventor

Michael TRENDLENBURG

Residence

D-69221 Dossenheim, Germany *Duf*

Citizenship

Germany

Post Office Address

Im Insenebuehl 21, D-69221 Dossenheim, Germany

Inventor's signature

*[Signature]*

Date

Jan 15, 2002

2002 JAN 15 16:46:50

<110> Deutsches Krebsforschungszentrum  
 <120> Molekularbiologische Marker für die analytische Elektronenmikroskopie  
 <130> K 2778  
 <140> PCT/DE00/00116  
 <141> 2000-01-07  
 <150> DE 199 00 511.7  
 <151> 1999-01-08  
 <160> 12  
 <170> PatentIn Ver. 2.1.

<210> 1  
 <211> 717  
 <212> DNA  
 <213> Künstliche Sequenz

<220>  
 <223> Beschreibung der künstlichen Sequenz: Plasmid mit 27x SK Primer

<400> 1

|   |     |
|---|-----|
| agctcgaaat taaccctcac taaaggaac aaaagctggt accggccgga tccactagtt  | 60  |
| ctagagcgat ctgatccact agttctagag cgatctgac cactagttct agagcgatct  | 120 |
| gatccactag ttctagagcg atctgatcca ctagttctag agcgatctga tccactagtt | 180 |
| ctagagcgat ctgatccact agttctagag cggccggatc cactagttct agagcgatct | 240 |
| gatccactag ttctagagcg atctgatcca ctagttctag agcgatctga tccactagtt | 300 |
| ctagagcgat ctgatccact agttctagag cgatctgac cactagttct agagcgatct  | 360 |
| gatccactag ttctagagcg gccggatcca ctagttctag agcgatctga tccactagtt | 420 |
| ctagagcgat ctgatccact agttctagag cgatctgac cactagttct agagcgatct  | 480 |
| gatccactag ttctagagcg atctgatcca ctagttctag agcgatctga tccactagtt | 540 |
| ctagagcgat ctgatccact agttctagag cgatctgac cactagttct agagcgatct  | 600 |
| gatccactag ttctagagcg atctgatcca ctagttctag agcgatctga tccactagtt | 660 |
| ctagagcgat ctgatccact agttctagag cggccgccac cgcggtggag ctccaat    | 717 |

<210> 2  
 <211> 26  
 <212> DNA  
 <213> Künstliche Sequenz

<220>  
 <223> Beschreibung der künstlichen Sequenz: SK Primer

09/914397 28 AUG 2001

<400> 2

ggggatccac tagttctaga gcggcc

26

<210> 3

<211> 38

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz: MCS SK Primer

<400> 3

gtaccgatcg gatccactag ttctagagcg atctgac

38

<210> 4

<211> 59

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz: Einschub in Plasmid mit 2 x SK Primern

<400> 4

gggtaccgat cggatccact agttctagag cgatctgac cactagttct agagcggcc

59

<210> 5

<211> 20

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz: SK Primer

<400> 5

gatccactag ttctagagcg

20

<210> 6

<211> 18

<212> DNA

<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz: M13 Primer

<400> 6

tgtaaaacga cggccagt

18

<210> 7

<211> 18

<212> DNA

<213> Künstliche Sequenz

004439 2647660

<220>  
<223> Beschreibung der künstlichen Sequenz: M13 Primer

<400> 7

caggaaacag ctatgacc

18

<210> 8  
<211> 20  
<212> DNA  
<213> Künstliche Sequenz

<220>  
<223> Beschreibung der künstlichen Sequenz: T3 Primer

<400> 8

aattaaccct cactaaaggg

20

<210> 9  
<211> 20  
<212> DNA  
<213> Künstliche Sequenz

<220>  
<223> Beschreibung der künstlichen Sequenz: T7 Primer

<400> 9

taatacgact cactataggg

20

<210> 10  
<211> 34  
<212> DNA  
<213> Künstliche Sequenz

<220>  
<223> Beschreibung der künstlichen Sequenz: Einschub in Plasmid mit 7x SK  
Primer

<400> 10

agttctagag cggccgccac cgcggtggag ctcc

34

<210> 11  
<211> 42  
<212> DNA  
<213> Künstliche Sequenz

<220>  
<223> Beschreibung der künstlichen Sequenz: Einschub in Plasmid mit 7x SK  
Primer

<400> 11

gtaccggccg gatccactag ttctagagcg atctgatcca ct

42

001000 0647660



<210> 12  
<211> 48  
<212> DNA  
<213> Künstliche Sequenz

<220>  
<223> Beschreibung der künstlichen Sequenz: Einschub in Plasmid mit 14x SK  
Primer

<400> 12

atctgatcca ctagttctag agcggccgga tccactagtt ctagagcg

48

201000 2647660